155 related articles for article (PubMed ID: 25434912)
1. Antiobesity drugs in early pregnancy and congenital malformations in the offspring.
Källén BA
Obes Res Clin Pract; 2014; 8(6):e571-6. PubMed ID: 25434912
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of weight-reducing drugs in hypertensive patients.
Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of weight-reducing drugs in hypertensive patients.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Siering U; Semlitsch T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007654. PubMed ID: 23543553
[TBL] [Abstract][Full Text] [Related]
6. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Padwal RS; Majumdar SR
Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
[TBL] [Abstract][Full Text] [Related]
7. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Rubio MA; Gargallo M; Isabel Millán A; Moreno B
Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
[TBL] [Abstract][Full Text] [Related]
8. [Drug treatment of obesity].
Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
[TBL] [Abstract][Full Text] [Related]
9. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio MJ; Wilton LV; Shakir SA
Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.
Gray LJ; Cooper N; Dunkley A; Warren FC; Ara R; Abrams K; Davies MJ; Khunti K; Sutton A
Obes Rev; 2012 Jun; 13(6):483-98. PubMed ID: 22288431
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy of obesity].
Hamann A
Internist (Berl); 2008 Jan; 49(1):106-13. PubMed ID: 18060334
[TBL] [Abstract][Full Text] [Related]
12. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
[TBL] [Abstract][Full Text] [Related]
13. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
14. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
[TBL] [Abstract][Full Text] [Related]
15. [Antiobesity drugs--new limitations].
Nau JY
Rev Med Suisse; 2007 Nov; 3(135):2753. PubMed ID: 18214233
[No Abstract] [Full Text] [Related]
16. Recent advances in obesity pharmacotherapy.
Mayer MA; Höcht C; Puyó A; Taira CA
Curr Clin Pharmacol; 2009 Jan; 4(1):53-61. PubMed ID: 19149502
[TBL] [Abstract][Full Text] [Related]
17. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.
Viner RM; Hsia Y; Neubert A; Wong IC
Br J Clin Pharmacol; 2009 Dec; 68(6):844-51. PubMed ID: 20002078
[TBL] [Abstract][Full Text] [Related]
18. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
Chaput JP; St-Pierre S; Tremblay A
Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for obesity.
Li M; Cheung BM
Br J Clin Pharmacol; 2009 Dec; 68(6):804-10. PubMed ID: 20002075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
